Oncology Based Preclinical CRO Market Research Report from 2023 forecast to 2029, by Manufacturers, Regions, Type and Application

The global Oncology Based Preclinical CRO market size was valued at USD 391.3 million in 2022 and is forecast to a readjusted size of USD 857.9 million by 2029 with a CAGR of 11.9% during review period.

Preclinical research refers to before testing a drug in people, researchers must find out whether it has the potential to cause serious harm, also called toxicity. A Preclinical CRO, or preclinical contract research organization, provides the experience, knowledge, and skill required to take a pharmaceutical product or medical device from the drawing board to distribution. This journey entails a plethora of activities that involve scientists, medical personnel, administrators, governmental and industry liaisons, marketing experts, and a host of other technical and creative individuals. Rarely is this unique combination of credentials and craft already present within a sponsoring organization. The CRO industry emerged to fill this much-needed role, to provide the expertise required to bring a pharmaceutical product or medical device into the marketplace as quickly and smoothly as possible.

The industry's leading producers are Crown Bioscience, Charles River and ICON, with revenues of 18.32 percent, 13.86 percent and 9.13 percent in 2019.

This report is a detailed and comprehensive analysis for global Oncology Based Preclinical CRO market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:

Global Oncology Based Preclinical CRO market size and forecasts, in consumption value ($ Million), 2018-2029
Global Oncology Based Preclinical CRO market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Oncology Based Preclinical CRO market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Oncology Based Preclinical CRO market shares of main players, in revenue ($ Million), 2018-2023

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Oncology Based Preclinical CRO
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace

This report profiles key players in the global Oncology Based Preclinical CRO market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

   Crown Bioscience
   Charles River
   ICON
   Eurofins Scientific
   Taconic Biosciences
   Covance
   EVOTEC
   The Jackson Laboratory
   MI Bioresearch
   Champion Oncology
   Wuxi AppTec.
   Xentech
   Living Tumor Laboratory

   Blood Cancer
   Solid Tumors
   Others

   In Vitro
   In Vivo

   North America (United States, Canada, and Mexico)
   Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
   Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
   South America (Brazil, Argentina and Rest of South America)
   Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

What are the strengths of the Oncology-Based Preclinical CRO Market in 2025?

The strengths include the increasing demand for targeted cancer therapies, which drives the need for specialized preclinical research. The market benefits from advancements in technology, such as AI and biomarker discovery, improving the accuracy and speed of drug development. Additionally, growing collaborations between pharmaceutical companies and contract research organizations (CROs) strengthen the market’s position.

What are the weaknesses in the Oncology-Based Preclinical CRO Market in 2025?

A major weakness is the high cost associated with preclinical trials, which can limit access for smaller biotech firms. Regulatory hurdles and the complexity of oncology drug development can also slow progress. Additionally, there is a shortage of skilled professionals in the field, potentially affecting the quality of research and slowing market growth.

What are the opportunities in the Oncology-Based Preclinical CRO Market in 2025?

Opportunities lie in the increasing global prevalence of cancer, driving more demand for cancer drug discovery and testing services. The market also has significant growth potential in emerging markets due to rising healthcare investments and better healthcare infrastructure. Moreover, partnerships with technology firms to enhance data analytics and streamline processes can provide new avenues for market growth.

What are the threats to the Oncology-Based Preclinical CRO Market in 2025?

Threats include the risk of increasing competition among CROs, which could drive down prices and impact profit margins. Additionally, regulatory changes and the slow approval process of new cancer therapies could delay project timelines. The economic instability in various regions can also limit funding for oncology research, posing a threat to market growth.

What are the political factors impacting the Oncology-Based Preclinical CRO Market in 2025?

Political factors, such as healthcare policies and government funding for cancer research, play a significant role in shaping the market. Government support for oncology research and drug development incentives can boost the market’s growth, while political instability or changes in healthcare laws could disrupt operations and funding.

What are the economic factors affecting the Oncology-Based Preclinical CRO Market in 2025?

Economic factors include the availability of funding for research and development in oncology, as well as the financial health of pharmaceutical companies. Economic downturns may lead to reduced investment in new oncology therapies, slowing market growth. However, strong economic performance in key markets can increase spending on cancer drug discovery and preclinical research.

What are the social factors influencing the Oncology-Based Preclinical CRO Market in 2025?

Increasing awareness about cancer and the growing demand for personalized medicine influence the market. Society's shift toward prioritizing healthcare and cancer treatment options is driving the need for more advanced preclinical studies. Additionally, an aging global population is contributing to higher cancer rates, increasing demand for oncology research services.

What are the technological factors impacting the Oncology-Based Preclinical CRO Market in 2025?

Technological advancements, particularly in AI, machine learning, and biomarker discovery, are revolutionizing the oncology preclinical space. These technologies enable faster, more precise drug testing and reduce costs. However, the high cost of implementing cutting-edge technologies could be a barrier for some smaller CROs, limiting their competitive edge.

What are the environmental factors affecting the Oncology-Based Preclinical CRO Market in 2025?

Environmental regulations related to clinical trials and laboratory practices can impact the market. CROs must adhere to sustainability practices in their operations, which can involve costs but also present opportunities for differentiation. Environmental factors such as climate change may also affect the supply chain for research materials or reagents used in preclinical studies.

What are the legal factors influencing the Oncology-Based Preclinical CRO Market in 2025?

Legal factors, including regulatory approvals, intellectual property laws, and clinical trial regulations, are crucial for the market’s success. The stringent regulations around clinical trials and drug testing in oncology can increase the time and cost required for drug development. Additionally, ensuring compliance with intellectual property laws is essential to protect new discoveries and technologies.

What are the suppliers in the Oncology-Based Preclinical CRO Market in 2025?

Suppliers include research institutions, technology providers (for AI and biomarker analytics), pharmaceutical companies, and vendors of laboratory equipment and reagents. Additionally, skilled labor providers, such as specialized researchers and clinical trial management organizations, also play a key role in the supply chain.

What are the inputs in the Oncology-Based Preclinical CRO Market in 2025?

Inputs involve raw materials like laboratory reagents, animal models, clinical trial data, technological tools for data analysis, and skilled professionals in oncology research. These are critical in carrying out effective preclinical trials and ensuring accurate results in oncology drug development.

What are the processes involved in the Oncology-Based Preclinical CRO Market in 2025?

Processes in the oncology preclinical CRO market include designing and conducting preclinical trials, developing animal models, performing drug efficacy and toxicity testing, analyzing results, and regulatory compliance procedures. The integration of advanced technologies like AI and data analytics enhances these processes for more effective drug discovery.

What are the outputs in the Oncology-Based Preclinical CRO Market in 2025?

Outputs include comprehensive preclinical trial data, including efficacy, safety profiles, and biomarker analysis for cancer therapies. These outputs are delivered to pharmaceutical companies and research organizations, enabling them to move forward with clinical trials and, eventually, the commercialization of oncology drugs.

What are the customers in the Oncology-Based Preclinical CRO Market in 2025?

Customers are primarily pharmaceutical companies, biotech firms, academic institutions, and other contract research organizations (CROs). These customers rely on the services of oncology-based preclinical CROs to accelerate their drug development processes, particularly for cancer treatments.

What is the threat of new entrants in the Oncology-Based Preclinical CRO Market in 2025?

The threat of new entrants is moderate. While the market has high growth potential, significant capital investment, regulatory compliance, and specialized expertise are required. These barriers make it challenging for new players to enter, but the increasing demand for oncology research services could attract some startups.

What is the bargaining power of suppliers in the Oncology-Based Preclinical CRO Market in 2025?

The bargaining power of suppliers is moderate to high. Suppliers of specialized materials, such as lab reagents and animal models, have some influence due to their critical role in the research process. However, the increasing availability of alternative suppliers and advancements in technology may help mitigate this power over time.

What is the bargaining power of buyers in the Oncology-Based Preclinical CRO Market in 2025?

The bargaining power of buyers is moderate. Pharmaceutical companies and biotech firms that require oncology research services have the option to choose from multiple CROs. However, due to the highly specialized nature of preclinical research, buyers are somewhat dependent on a few established players with proven expertise and capabilities.

What is the threat of substitute products or services in the Oncology-Based Preclinical CRO Market in 2025?

The threat of substitutes is relatively low. Preclinical CROs provide specialized, indispensable services in oncology drug development, and while in-house research departments or alternative models could serve as substitutes, they often lack the expertise and resources of established CROs, making them less viable for large-scale oncology research.

What is the intensity of competitive rivalry in the Oncology-Based Preclinical CRO Market in 2025?

The intensity of competitive rivalry is high. With the growing demand for oncology treatments, several established players and emerging CROs are competing for market share. Price competition, service differentiation, and technological advancements are key factors driving this rivalry in the market.

What are the key upstream drivers in the Oncology-Based Preclinical CRO Market in 2025?

Upstream drivers include the increasing demand for innovative cancer therapies, advancements in biotechnology, and growing investments in cancer research. Additionally, collaborations between pharmaceutical companies, biotech firms, and academic institutions fuel the need for specialized preclinical services. The ongoing evolution of cancer genomics and precision medicine also plays a critical role in driving demand for tailored preclinical research.

What are the upstream challenges faced by the Oncology-Based Preclinical CRO Market in 2025?

Upstream challenges involve high costs associated with cutting-edge research and the need for specialized equipment, reagents, and skilled personnel. Regulatory complexities and the long timelines for oncology drug development add to the difficulty. Furthermore, the shortage of qualified professionals in oncology research and development may restrict growth in this segment.

What are the key upstream resources required in the Oncology-Based Preclinical CRO Market in 2025?

Key upstream resources include advanced laboratory equipment, animal models for testing, access to cutting-edge technologies like AI for data analysis, and reagents for drug testing. A skilled workforce, including research scientists, regulatory experts, and technicians, is also critical to support high-quality preclinical trials and research initiatives.

What role do suppliers play in the upstream segment of the Oncology-Based Preclinical CRO Market in 2025?

Suppliers play a crucial role by providing the essential materials, technologies, and expertise needed for preclinical trials. This includes delivering laboratory reagents, offering animal model systems, and supplying software or technology for data analytics. Suppliers of specialized tools for molecular testing and advanced imaging also contribute significantly to the upstream value chain.

What are the upstream trends shaping the Oncology-Based Preclinical CRO Market in 2025?

Upstream trends include a rising focus on personalized medicine and the integration of artificial intelligence in drug discovery. Additionally, there is increasing demand for more advanced and efficient animal models, as well as better biomarker discovery tools to improve preclinical trial outcomes. Collaboration with tech companies to streamline data analysis and accelerate the drug development process is also an emerging trend.

What are the key midstream activities in the Oncology-Based Preclinical CRO Market in 2025?

Key midstream activities include the execution of preclinical trials, data collection, analysis, and interpretation of results. This stage also involves the development and validation of animal models, conducting safety and efficacy assessments, and preparing regulatory documentation for the transition to clinical trials. CROs also provide project management and regulatory consulting services to guide the process.

What challenges exist in the midstream of the Oncology-Based Preclinical CRO Market in 2025?

Challenges in the midstream include managing the complexity and variability of preclinical trial results, as well as ensuring compliance with constantly evolving regulations. Additionally, data integrity and reproducibility issues can hinder progress, and maintaining the timelines for drug development amidst unforeseen delays or technical challenges is another obstacle for CROs.

How does the integration of technology impact the midstream of the Oncology-Based Preclinical CRO Market in 2025?

Technology plays a significant role in improving data analysis, accelerating the drug discovery process, and enhancing the precision of preclinical studies. Tools such as artificial intelligence, machine learning, and high-throughput screening platforms streamline the process of identifying promising candidates, while innovations in genomics and imaging techniques improve model accuracy and efficiency.

What are the key players involved in the midstream of the Oncology-Based Preclinical CRO Market in 2025?

Key players include contract research organizations (CROs) that specialize in oncology, research institutions, biotech companies, and pharmaceutical firms that provide funding or drug candidates for testing. These entities work collaboratively to conduct preclinical research, manage trials, and ensure the smooth progression of promising therapies to clinical development.

How do regulatory bodies influence the midstream of the Oncology-Based Preclinical CRO Market in 2025?

Regulatory bodies, such as the FDA, EMA, and other local health authorities, have a significant influence on midstream activities. They establish guidelines for the conduct of preclinical trials, ensuring that safety and ethical standards are upheld. These agencies also review data from preclinical studies to approve new drugs for clinical trials, thus directly impacting the speed and success of drug development.

What are the key downstream activities in the Oncology-Based Preclinical CRO Market in 2025?

Key downstream activities include the transition of preclinical trial results to clinical stages, regulatory submission for clinical trial approval, and commercialization of successful oncology therapies. This stage also involves the collaboration with clinical trial organizations, pharmaceutical companies, and healthcare providers to move drugs from research to patient treatment.

What challenges are faced in the downstream segment of the Oncology-Based Preclinical CRO Market in 2025?

Challenges in the downstream segment include the long and costly process of regulatory approvals, as well as ensuring successful translation of preclinical results to human clinical trials. Additionally, market competition and pricing pressures from both established and emerging therapies may influence the speed and scope of commercialization.

How do customer relationships impact the downstream of the Oncology-Based Preclinical CRO Market in 2025?

Customer relationships are crucial in the downstream market, as long-term collaborations between CROs and pharmaceutical companies lead to ongoing business and repeat contracts. Trust and reliability in delivering quality preclinical data, along with strong post-trial support and regulatory guidance, enhance customer loyalty and can ensure successful product launches.

What role do commercialization strategies play in the downstream of the Oncology-Based Preclinical CRO Market in 2025?

Commercialization strategies are critical for transitioning successful preclinical outcomes into profitable marketable drugs. These strategies include partnerships with larger pharmaceutical companies for marketing and distribution, as well as the effective management of intellectual property rights and pricing strategies to ensure competitive advantage.

What downstream trends are shaping the Oncology-Based Preclinical CRO Market in 2025?

Trends include increasing reliance on personalized oncology therapies, which requires precise data from preclinical studies to support clinical applications. The rise of targeted therapies and immuno-oncology also drives the need for more sophisticated downstream strategies, including detailed biomarker testing and patient stratification methods. Additionally, there’s a growing emphasis on faster time-to-market for oncology drugs, encouraging closer collaboration between CROs, pharmaceutical companies, and regulatory bodies.

Chapter 1, to describe Oncology Based Preclinical CRO product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Oncology Based Preclinical CRO, with revenue, gross margin and global market share of Oncology Based Preclinical CRO from 2018 to 2023.
Chapter 3, the Oncology Based Preclinical CRO competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Oncology Based Preclinical CRO market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Oncology Based Preclinical CRO.
Chapter 13, to describe Oncology Based Preclinical CRO research findings and conclusion.

1 Market Overview

   1.1 Product Overview and Scope of Oncology Based Preclinical CRO
   1.2 Market Estimation Caveats and Base Year
   1.3 Classification of Oncology Based Preclinical CRO by Type
       1.3.1 Overview: Global Oncology Based Preclinical CRO Market Size by Type: 2018 Versus 2022 Versus 2029
       1.3.2 Global Oncology Based Preclinical CRO Consumption Value Market Share by Type in 2022
       1.3.3 Blood Cancer
       1.3.4 Solid Tumors
       1.3.5 Others
   1.4 Global Oncology Based Preclinical CRO Market by Application
       1.4.1 Overview: Global Oncology Based Preclinical CRO Market Size by Application: 2018 Versus 2022 Versus 2029
       1.4.2 In Vitro
       1.4.3 In Vivo
   1.5 Global Oncology Based Preclinical CRO Market Size & Forecast
   1.6 Global Oncology Based Preclinical CRO Market Size and Forecast by Region
       1.6.1 Global Oncology Based Preclinical CRO Market Size by Region: 2018 VS 2022 VS 2029
       1.6.2 Global Oncology Based Preclinical CRO Market Size by Region, (2018-2029)
       1.6.3 North America Oncology Based Preclinical CRO Market Size and Prospect (2018-2029)
       1.6.4 Europe Oncology Based Preclinical CRO Market Size and Prospect (2018-2029)
       1.6.5 Asia-Pacific Oncology Based Preclinical CRO Market Size and Prospect (2018-2029)
       1.6.6 South America Oncology Based Preclinical CRO Market Size and Prospect (2018-2029)
       1.6.7 Middle East and Africa Oncology Based Preclinical CRO Market Size and Prospect (2018-2029)

2 Company Profiles

   2.1 Crown Bioscience
       2.1.1 Crown Bioscience Details
       2.1.2 Crown Bioscience Major Business
       2.1.3 Crown Bioscience Oncology Based Preclinical CRO Product and Solutions
       2.1.4 Crown Bioscience Oncology Based Preclinical CRO Revenue, Gross Margin and Market Share (2018-2023)
       2.1.5 Crown Bioscience Recent Developments and Future Plans
   2.2 Charles River
       2.2.1 Charles River Details
       2.2.2 Charles River Major Business
       2.2.3 Charles River Oncology Based Preclinical CRO Product and Solutions
       2.2.4 Charles River Oncology Based Preclinical CRO Revenue, Gross Margin and Market Share (2018-2023)
       2.2.5 Charles River Recent Developments and Future Plans
   2.3 ICON
       2.3.1 ICON Details
       2.3.2 ICON Major Business
       2.3.3 ICON Oncology Based Preclinical CRO Product and Solutions
       2.3.4 ICON Oncology Based Preclinical CRO Revenue, Gross Margin and Market Share (2018-2023)
       2.3.5 ICON Recent Developments and Future Plans
   2.4 Eurofins Scientific
       2.4.1 Eurofins Scientific Details
       2.4.2 Eurofins Scientific Major Business
       2.4.3 Eurofins Scientific Oncology Based Preclinical CRO Product and Solutions
       2.4.4 Eurofins Scientific Oncology Based Preclinical CRO Revenue, Gross Margin and Market Share (2018-2023)
       2.4.5 Eurofins Scientific Recent Developments and Future Plans
   2.5 Taconic Biosciences
       2.5.1 Taconic Biosciences Details
       2.5.2 Taconic Biosciences Major Business
       2.5.3 Taconic Biosciences Oncology Based Preclinical CRO Product and Solutions
       2.5.4 Taconic Biosciences Oncology Based Preclinical CRO Revenue, Gross Margin and Market Share (2018-2023)
       2.5.5 Taconic Biosciences Recent Developments and Future Plans
   2.6 Covance
       2.6.1 Covance Details
       2.6.2 Covance Major Business
       2.6.3 Covance Oncology Based Preclinical CRO Product and Solutions
       2.6.4 Covance Oncology Based Preclinical CRO Revenue, Gross Margin and Market Share (2018-2023)
       2.6.5 Covance Recent Developments and Future Plans
   2.7 EVOTEC
       2.7.1 EVOTEC Details
       2.7.2 EVOTEC Major Business
       2.7.3 EVOTEC Oncology Based Preclinical CRO Product and Solutions
       2.7.4 EVOTEC Oncology Based Preclinical CRO Revenue, Gross Margin and Market Share (2018-2023)
       2.7.5 EVOTEC Recent Developments and Future Plans
   2.8 The Jackson Laboratory
       2.8.1 The Jackson Laboratory Details
       2.8.2 The Jackson Laboratory Major Business
       2.8.3 The Jackson Laboratory Oncology Based Preclinical CRO Product and Solutions
       2.8.4 The Jackson Laboratory Oncology Based Preclinical CRO Revenue, Gross Margin and Market Share (2018-2023)
       2.8.5 The Jackson Laboratory Recent Developments and Future Plans
   2.9 MI Bioresearch
       2.9.1 MI Bioresearch Details
       2.9.2 MI Bioresearch Major Business
       2.9.3 MI Bioresearch Oncology Based Preclinical CRO Product and Solutions
       2.9.4 MI Bioresearch Oncology Based Preclinical CRO Revenue, Gross Margin and Market Share (2018-2023)
       2.9.5 MI Bioresearch Recent Developments and Future Plans
   2.10 Champion Oncology 
       2.10.1 Champion Oncology Details
       2.10.2 Champion Oncology Major Business
       2.10.3 Champion Oncology Oncology Based Preclinical CRO Product and Solutions
       2.10.4 Champion Oncology Oncology Based Preclinical CRO Revenue, Gross Margin and Market Share (2018-2023)
       2.10.5 Champion Oncology Recent Developments and Future Plans
   2.11 Wuxi AppTec.
       2.11.1 Wuxi AppTec. Details
       2.11.2 Wuxi AppTec. Major Business
       2.11.3 Wuxi AppTec. Oncology Based Preclinical CRO Product and Solutions
       2.11.4 Wuxi AppTec. Oncology Based Preclinical CRO Revenue, Gross Margin and Market Share (2018-2023)
       2.11.5 Wuxi AppTec. Recent Developments and Future Plans
   2.12 Xentech
       2.12.1 Xentech Details
       2.12.2 Xentech Major Business
       2.12.3 Xentech Oncology Based Preclinical CRO Product and Solutions
       2.12.4 Xentech Oncology Based Preclinical CRO Revenue, Gross Margin and Market Share (2018-2023)
       2.12.5 Xentech Recent Developments and Future Plans
   2.13 Living Tumor Laboratory
       2.13.1 Living Tumor Laboratory Details
       2.13.2 Living Tumor Laboratory Major Business
       2.13.3 Living Tumor Laboratory Oncology Based Preclinical CRO Product and Solutions
       2.13.4 Living Tumor Laboratory Oncology Based Preclinical CRO Revenue, Gross Margin and Market Share (2018-2023)
       2.13.5 Living Tumor Laboratory Recent Developments and Future Plans

3 Market Competition, by Players

   3.1 Global Oncology Based Preclinical CRO Revenue and Share by Players (2018-2023)
   3.2 Market Share Analysis (2022)
       3.2.1 Market Share of Oncology Based Preclinical CRO by Company Revenue
       3.2.2 Top 3 Oncology Based Preclinical CRO Players Market Share in 2022
       3.2.3 Top 6 Oncology Based Preclinical CRO Players Market Share in 2022
   3.3 Oncology Based Preclinical CRO Market: Overall Company Footprint Analysis
       3.3.1 Oncology Based Preclinical CRO Market: Region Footprint
       3.3.2 Oncology Based Preclinical CRO Market: Company Product Type Footprint
       3.3.3 Oncology Based Preclinical CRO Market: Company Product Application Footprint
   3.4 New Market Entrants and Barriers to Market Entry
   3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

   4.1 Global Oncology Based Preclinical CRO Consumption Value and Market Share by Type (2018-2023)
   4.2 Global Oncology Based Preclinical CRO Market Forecast by Type (2024-2029)

5 Market Size Segment by Application

   5.1 Global Oncology Based Preclinical CRO Consumption Value Market Share by Application (2018-2023)
   5.2 Global Oncology Based Preclinical CRO Market Forecast by Application (2024-2029)

6 North America

   6.1 North America Oncology Based Preclinical CRO Consumption Value by Type (2018-2029)
   6.2 North America Oncology Based Preclinical CRO Consumption Value by Application (2018-2029)
   6.3 North America Oncology Based Preclinical CRO Market Size by Country
       6.3.1 North America Oncology Based Preclinical CRO Consumption Value by Country (2018-2029)
       6.3.2 United States Oncology Based Preclinical CRO Market Size and Forecast (2018-2029)
       6.3.3 Canada Oncology Based Preclinical CRO Market Size and Forecast (2018-2029)
       6.3.4 Mexico Oncology Based Preclinical CRO Market Size and Forecast (2018-2029)

7 Europe

   7.1 Europe Oncology Based Preclinical CRO Consumption Value by Type (2018-2029)
   7.2 Europe Oncology Based Preclinical CRO Consumption Value by Application (2018-2029)
   7.3 Europe Oncology Based Preclinical CRO Market Size by Country
       7.3.1 Europe Oncology Based Preclinical CRO Consumption Value by Country (2018-2029)
       7.3.2 Germany Oncology Based Preclinical CRO Market Size and Forecast (2018-2029)
       7.3.3 France Oncology Based Preclinical CRO Market Size and Forecast (2018-2029)
       7.3.4 United Kingdom Oncology Based Preclinical CRO Market Size and Forecast (2018-2029)
       7.3.5 Russia Oncology Based Preclinical CRO Market Size and Forecast (2018-2029)
       7.3.6 Italy Oncology Based Preclinical CRO Market Size and Forecast (2018-2029)

8 Asia-Pacific

   8.1 Asia-Pacific Oncology Based Preclinical CRO Consumption Value by Type (2018-2029)
   8.2 Asia-Pacific Oncology Based Preclinical CRO Consumption Value by Application (2018-2029)
   8.3 Asia-Pacific Oncology Based Preclinical CRO Market Size by Region
       8.3.1 Asia-Pacific Oncology Based Preclinical CRO Consumption Value by Region (2018-2029)
       8.3.2 China Oncology Based Preclinical CRO Market Size and Forecast (2018-2029)
       8.3.3 Japan Oncology Based Preclinical CRO Market Size and Forecast (2018-2029)
       8.3.4 South Korea Oncology Based Preclinical CRO Market Size and Forecast (2018-2029)
       8.3.5 India Oncology Based Preclinical CRO Market Size and Forecast (2018-2029)
       8.3.6 Southeast Asia Oncology Based Preclinical CRO Market Size and Forecast (2018-2029)
       8.3.7 Australia Oncology Based Preclinical CRO Market Size and Forecast (2018-2029)

9 South America

   9.1 South America Oncology Based Preclinical CRO Consumption Value by Type (2018-2029)
   9.2 South America Oncology Based Preclinical CRO Consumption Value by Application (2018-2029)
   9.3 South America Oncology Based Preclinical CRO Market Size by Country
       9.3.1 South America Oncology Based Preclinical CRO Consumption Value by Country (2018-2029)
       9.3.2 Brazil Oncology Based Preclinical CRO Market Size and Forecast (2018-2029)
       9.3.3 Argentina Oncology Based Preclinical CRO Market Size and Forecast (2018-2029)

10 Middle East & Africa

   10.1 Middle East & Africa Oncology Based Preclinical CRO Consumption Value by Type (2018-2029)
   10.2 Middle East & Africa Oncology Based Preclinical CRO Consumption Value by Application (2018-2029)
   10.3 Middle East & Africa Oncology Based Preclinical CRO Market Size by Country
       10.3.1 Middle East & Africa Oncology Based Preclinical CRO Consumption Value by Country (2018-2029)
       10.3.2 Turkey Oncology Based Preclinical CRO Market Size and Forecast (2018-2029)
       10.3.3 Saudi Arabia Oncology Based Preclinical CRO Market Size and Forecast (2018-2029)
       10.3.4 UAE Oncology Based Preclinical CRO Market Size and Forecast (2018-2029)

11 Market Dynamics

   11.1 Oncology Based Preclinical CRO Market Drivers
   11.2 Oncology Based Preclinical CRO Market Restraints
   11.3 Oncology Based Preclinical CRO Trends Analysis
   11.4 Porters Five Forces Analysis
       11.4.1 Threat of New Entrants
       11.4.2 Bargaining Power of Suppliers
       11.4.3 Bargaining Power of Buyers
       11.4.4 Threat of Substitutes
       11.4.5 Competitive Rivalry
   11.5 Influence of COVID-19 and Russia-Ukraine War
       11.5.1 Influence of COVID-19
       11.5.2 Influence of Russia-Ukraine War

12 Industry Chain Analysis

   12.1 Oncology Based Preclinical CRO Industry Chain
   12.2 Oncology Based Preclinical CRO Upstream Analysis
   12.3 Oncology Based Preclinical CRO Midstream Analysis
   12.4 Oncology Based Preclinical CRO Downstream Analysis

13 Research Findings and Conclusion

14 Appendix

   14.1 Methodology
   14.2 Research Process and Data Source
   14.3 Disclaimer

List of Tables

   Table 1. Global Oncology Based Preclinical CRO Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
   Table 2. Global Oncology Based Preclinical CRO Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
   Table 3. Global Oncology Based Preclinical CRO Consumption Value by Region (2018-2023) & (USD Million)
   Table 4. Global Oncology Based Preclinical CRO Consumption Value by Region (2024-2029) & (USD Million)
   Table 5. Crown Bioscience Company Information, Head Office, and Major Competitors
   Table 6. Crown Bioscience Major Business
   Table 7. Crown Bioscience Oncology Based Preclinical CRO Product and Solutions
   Table 8. Crown Bioscience Oncology Based Preclinical CRO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 9. Crown Bioscience Recent Developments and Future Plans
   Table 10. Charles River Company Information, Head Office, and Major Competitors
   Table 11. Charles River Major Business
   Table 12. Charles River Oncology Based Preclinical CRO Product and Solutions
   Table 13. Charles River Oncology Based Preclinical CRO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 14. Charles River Recent Developments and Future Plans
   Table 15. ICON Company Information, Head Office, and Major Competitors
   Table 16. ICON Major Business
   Table 17. ICON Oncology Based Preclinical CRO Product and Solutions
   Table 18. ICON Oncology Based Preclinical CRO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 19. ICON Recent Developments and Future Plans
   Table 20. Eurofins Scientific Company Information, Head Office, and Major Competitors
   Table 21. Eurofins Scientific Major Business
   Table 22. Eurofins Scientific Oncology Based Preclinical CRO Product and Solutions
   Table 23. Eurofins Scientific Oncology Based Preclinical CRO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 24. Eurofins Scientific Recent Developments and Future Plans
   Table 25. Taconic Biosciences Company Information, Head Office, and Major Competitors
   Table 26. Taconic Biosciences Major Business
   Table 27. Taconic Biosciences Oncology Based Preclinical CRO Product and Solutions
   Table 28. Taconic Biosciences Oncology Based Preclinical CRO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 29. Taconic Biosciences Recent Developments and Future Plans
   Table 30. Covance Company Information, Head Office, and Major Competitors
   Table 31. Covance Major Business
   Table 32. Covance Oncology Based Preclinical CRO Product and Solutions
   Table 33. Covance Oncology Based Preclinical CRO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 34. Covance Recent Developments and Future Plans
   Table 35. EVOTEC Company Information, Head Office, and Major Competitors
   Table 36. EVOTEC Major Business
   Table 37. EVOTEC Oncology Based Preclinical CRO Product and Solutions
   Table 38. EVOTEC Oncology Based Preclinical CRO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 39. EVOTEC Recent Developments and Future Plans
   Table 40. The Jackson Laboratory Company Information, Head Office, and Major Competitors
   Table 41. The Jackson Laboratory Major Business
   Table 42. The Jackson Laboratory Oncology Based Preclinical CRO Product and Solutions
   Table 43. The Jackson Laboratory Oncology Based Preclinical CRO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 44. The Jackson Laboratory Recent Developments and Future Plans
   Table 45. MI Bioresearch Company Information, Head Office, and Major Competitors
   Table 46. MI Bioresearch Major Business
   Table 47. MI Bioresearch Oncology Based Preclinical CRO Product and Solutions
   Table 48. MI Bioresearch Oncology Based Preclinical CRO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 49. MI Bioresearch Recent Developments and Future Plans
   Table 50. Champion Oncology Company Information, Head Office, and Major Competitors
   Table 51. Champion Oncology Major Business
   Table 52. Champion Oncology Oncology Based Preclinical CRO Product and Solutions
   Table 53. Champion Oncology Oncology Based Preclinical CRO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 54. Champion Oncology Recent Developments and Future Plans
   Table 55. Wuxi AppTec. Company Information, Head Office, and Major Competitors
   Table 56. Wuxi AppTec. Major Business
   Table 57. Wuxi AppTec. Oncology Based Preclinical CRO Product and Solutions
   Table 58. Wuxi AppTec. Oncology Based Preclinical CRO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 59. Wuxi AppTec. Recent Developments and Future Plans
   Table 60. Xentech Company Information, Head Office, and Major Competitors
   Table 61. Xentech Major Business
   Table 62. Xentech Oncology Based Preclinical CRO Product and Solutions
   Table 63. Xentech Oncology Based Preclinical CRO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 64. Xentech Recent Developments and Future Plans
   Table 65. Living Tumor Laboratory Company Information, Head Office, and Major Competitors
   Table 66. Living Tumor Laboratory Major Business
   Table 67. Living Tumor Laboratory Oncology Based Preclinical CRO Product and Solutions
   Table 68. Living Tumor Laboratory Oncology Based Preclinical CRO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 69. Living Tumor Laboratory Recent Developments and Future Plans
   Table 70. Global Oncology Based Preclinical CRO Revenue (USD Million) by Players (2018-2023)
   Table 71. Global Oncology Based Preclinical CRO Revenue Share by Players (2018-2023)
   Table 72. Breakdown of Oncology Based Preclinical CRO by Company Type (Tier 1, Tier 2, and Tier 3)
   Table 73. Market Position of Players in Oncology Based Preclinical CRO, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
   Table 74. Head Office of Key Oncology Based Preclinical CRO Players
   Table 75. Oncology Based Preclinical CRO Market: Company Product Type Footprint
   Table 76. Oncology Based Preclinical CRO Market: Company Product Application Footprint
   Table 77. Oncology Based Preclinical CRO New Market Entrants and Barriers to Market Entry
   Table 78. Oncology Based Preclinical CRO Mergers, Acquisition, Agreements, and Collaborations
   Table 79. Global Oncology Based Preclinical CRO Consumption Value (USD Million) by Type (2018-2023)
   Table 80. Global Oncology Based Preclinical CRO Consumption Value Share by Type (2018-2023)
   Table 81. Global Oncology Based Preclinical CRO Consumption Value Forecast by Type (2024-2029)
   Table 82. Global Oncology Based Preclinical CRO Consumption Value by Application (2018-2023)
   Table 83. Global Oncology Based Preclinical CRO Consumption Value Forecast by Application (2024-2029)
   Table 84. North America Oncology Based Preclinical CRO Consumption Value by Type (2018-2023) & (USD Million)
   Table 85. North America Oncology Based Preclinical CRO Consumption Value by Type (2024-2029) & (USD Million)
   Table 86. North America Oncology Based Preclinical CRO Consumption Value by Application (2018-2023) & (USD Million)
   Table 87. North America Oncology Based Preclinical CRO Consumption Value by Application (2024-2029) & (USD Million)
   Table 88. North America Oncology Based Preclinical CRO Consumption Value by Country (2018-2023) & (USD Million)
   Table 89. North America Oncology Based Preclinical CRO Consumption Value by Country (2024-2029) & (USD Million)
   Table 90. Europe Oncology Based Preclinical CRO Consumption Value by Type (2018-2023) & (USD Million)
   Table 91. Europe Oncology Based Preclinical CRO Consumption Value by Type (2024-2029) & (USD Million)
   Table 92. Europe Oncology Based Preclinical CRO Consumption Value by Application (2018-2023) & (USD Million)
   Table 93. Europe Oncology Based Preclinical CRO Consumption Value by Application (2024-2029) & (USD Million)
   Table 94. Europe Oncology Based Preclinical CRO Consumption Value by Country (2018-2023) & (USD Million)
   Table 95. Europe Oncology Based Preclinical CRO Consumption Value by Country (2024-2029) & (USD Million)
   Table 96. Asia-Pacific Oncology Based Preclinical CRO Consumption Value by Type (2018-2023) & (USD Million)
   Table 97. Asia-Pacific Oncology Based Preclinical CRO Consumption Value by Type (2024-2029) & (USD Million)
   Table 98. Asia-Pacific Oncology Based Preclinical CRO Consumption Value by Application (2018-2023) & (USD Million)
   Table 99. Asia-Pacific Oncology Based Preclinical CRO Consumption Value by Application (2024-2029) & (USD Million)
   Table 100. Asia-Pacific Oncology Based Preclinical CRO Consumption Value by Region (2018-2023) & (USD Million)
   Table 101. Asia-Pacific Oncology Based Preclinical CRO Consumption Value by Region (2024-2029) & (USD Million)
   Table 102. South America Oncology Based Preclinical CRO Consumption Value by Type (2018-2023) & (USD Million)
   Table 103. South America Oncology Based Preclinical CRO Consumption Value by Type (2024-2029) & (USD Million)
   Table 104. South America Oncology Based Preclinical CRO Consumption Value by Application (2018-2023) & (USD Million)
   Table 105. South America Oncology Based Preclinical CRO Consumption Value by Application (2024-2029) & (USD Million)
   Table 106. South America Oncology Based Preclinical CRO Consumption Value by Country (2018-2023) & (USD Million)
   Table 107. South America Oncology Based Preclinical CRO Consumption Value by Country (2024-2029) & (USD Million)
   Table 108. Middle East & Africa Oncology Based Preclinical CRO Consumption Value by Type (2018-2023) & (USD Million)
   Table 109. Middle East & Africa Oncology Based Preclinical CRO Consumption Value by Type (2024-2029) & (USD Million)
   Table 110. Middle East & Africa Oncology Based Preclinical CRO Consumption Value by Application (2018-2023) & (USD Million)
   Table 111. Middle East & Africa Oncology Based Preclinical CRO Consumption Value by Application (2024-2029) & (USD Million)
   Table 112. Middle East & Africa Oncology Based Preclinical CRO Consumption Value by Country (2018-2023) & (USD Million)
   Table 113. Middle East & Africa Oncology Based Preclinical CRO Consumption Value by Country (2024-2029) & (USD Million)
   Table 114. Oncology Based Preclinical CRO Raw Material
   Table 115. Key Suppliers of Oncology Based Preclinical CRO Raw Materials

List of Figures

   Figure 1. Oncology Based Preclinical CRO Picture
   Figure 2. Global Oncology Based Preclinical CRO Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
   Figure 3. Global Oncology Based Preclinical CRO Consumption Value Market Share by Type in 2022
   Figure 4. Blood Cancer
   Figure 5. Solid Tumors
   Figure 6. Others
   Figure 7. Global Oncology Based Preclinical CRO Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
   Figure 8. Oncology Based Preclinical CRO Consumption Value Market Share by Application in 2022
   Figure 9. In Vitro Picture
   Figure 10. In Vivo Picture
   Figure 11. Global Oncology Based Preclinical CRO Consumption Value, (USD Million): 2018 & 2022 & 2029
   Figure 12. Global Oncology Based Preclinical CRO Consumption Value and Forecast (2018-2029) & (USD Million)
   Figure 13. Global Market Oncology Based Preclinical CRO Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
   Figure 14. Global Oncology Based Preclinical CRO Consumption Value Market Share by Region (2018-2029)
   Figure 15. Global Oncology Based Preclinical CRO Consumption Value Market Share by Region in 2022
   Figure 16. North America Oncology Based Preclinical CRO Consumption Value (2018-2029) & (USD Million)
   Figure 17. Europe Oncology Based Preclinical CRO Consumption Value (2018-2029) & (USD Million)
   Figure 18. Asia-Pacific Oncology Based Preclinical CRO Consumption Value (2018-2029) & (USD Million)
   Figure 19. South America Oncology Based Preclinical CRO Consumption Value (2018-2029) & (USD Million)
   Figure 20. Middle East and Africa Oncology Based Preclinical CRO Consumption Value (2018-2029) & (USD Million)
   Figure 21. Global Oncology Based Preclinical CRO Revenue Share by Players in 2022
   Figure 22. Oncology Based Preclinical CRO Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
   Figure 23. Global Top 3 Players Oncology Based Preclinical CRO Market Share in 2022
   Figure 24. Global Top 6 Players Oncology Based Preclinical CRO Market Share in 2022
   Figure 25. Global Oncology Based Preclinical CRO Consumption Value Share by Type (2018-2023)
   Figure 26. Global Oncology Based Preclinical CRO Market Share Forecast by Type (2024-2029)
   Figure 27. Global Oncology Based Preclinical CRO Consumption Value Share by Application (2018-2023)
   Figure 28. Global Oncology Based Preclinical CRO Market Share Forecast by Application (2024-2029)
   Figure 29. North America Oncology Based Preclinical CRO Consumption Value Market Share by Type (2018-2029)
   Figure 30. North America Oncology Based Preclinical CRO Consumption Value Market Share by Application (2018-2029)
   Figure 31. North America Oncology Based Preclinical CRO Consumption Value Market Share by Country (2018-2029)
   Figure 32. United States Oncology Based Preclinical CRO Consumption Value (2018-2029) & (USD Million)
   Figure 33. Canada Oncology Based Preclinical CRO Consumption Value (2018-2029) & (USD Million)
   Figure 34. Mexico Oncology Based Preclinical CRO Consumption Value (2018-2029) & (USD Million)
   Figure 35. Europe Oncology Based Preclinical CRO Consumption Value Market Share by Type (2018-2029)
   Figure 36. Europe Oncology Based Preclinical CRO Consumption Value Market Share by Application (2018-2029)
   Figure 37. Europe Oncology Based Preclinical CRO Consumption Value Market Share by Country (2018-2029)
   Figure 38. Germany Oncology Based Preclinical CRO Consumption Value (2018-2029) & (USD Million)
   Figure 39. France Oncology Based Preclinical CRO Consumption Value (2018-2029) & (USD Million)
   Figure 40. United Kingdom Oncology Based Preclinical CRO Consumption Value (2018-2029) & (USD Million)
   Figure 41. Russia Oncology Based Preclinical CRO Consumption Value (2018-2029) & (USD Million)
   Figure 42. Italy Oncology Based Preclinical CRO Consumption Value (2018-2029) & (USD Million)
   Figure 43. Asia-Pacific Oncology Based Preclinical CRO Consumption Value Market Share by Type (2018-2029)
   Figure 44. Asia-Pacific Oncology Based Preclinical CRO Consumption Value Market Share by Application (2018-2029)
   Figure 45. Asia-Pacific Oncology Based Preclinical CRO Consumption Value Market Share by Region (2018-2029)
   Figure 46. China Oncology Based Preclinical CRO Consumption Value (2018-2029) & (USD Million)
   Figure 47. Japan Oncology Based Preclinical CRO Consumption Value (2018-2029) & (USD Million)
   Figure 48. South Korea Oncology Based Preclinical CRO Consumption Value (2018-2029) & (USD Million)
   Figure 49. India Oncology Based Preclinical CRO Consumption Value (2018-2029) & (USD Million)
   Figure 50. Southeast Asia Oncology Based Preclinical CRO Consumption Value (2018-2029) & (USD Million)
   Figure 51. Australia Oncology Based Preclinical CRO Consumption Value (2018-2029) & (USD Million)
   Figure 52. South America Oncology Based Preclinical CRO Consumption Value Market Share by Type (2018-2029)
   Figure 53. South America Oncology Based Preclinical CRO Consumption Value Market Share by Application (2018-2029)
   Figure 54. South America Oncology Based Preclinical CRO Consumption Value Market Share by Country (2018-2029)
   Figure 55. Brazil Oncology Based Preclinical CRO Consumption Value (2018-2029) & (USD Million)
   Figure 56. Argentina Oncology Based Preclinical CRO Consumption Value (2018-2029) & (USD Million)
   Figure 57. Middle East and Africa Oncology Based Preclinical CRO Consumption Value Market Share by Type (2018-2029)
   Figure 58. Middle East and Africa Oncology Based Preclinical CRO Consumption Value Market Share by Application (2018-2029)
   Figure 59. Middle East and Africa Oncology Based Preclinical CRO Consumption Value Market Share by Country (2018-2029)
   Figure 60. Turkey Oncology Based Preclinical CRO Consumption Value (2018-2029) & (USD Million)
   Figure 61. Saudi Arabia Oncology Based Preclinical CRO Consumption Value (2018-2029) & (USD Million)
   Figure 62. UAE Oncology Based Preclinical CRO Consumption Value (2018-2029) & (USD Million)
   Figure 63. Oncology Based Preclinical CRO Market Drivers
   Figure 64. Oncology Based Preclinical CRO Market Restraints
   Figure 65. Oncology Based Preclinical CRO Market Trends
   Figure 66. Porters Five Forces Analysis
   Figure 67. Manufacturing Cost Structure Analysis of Oncology Based Preclinical CRO in 2022
   Figure 68. Manufacturing Process Analysis of Oncology Based Preclinical CRO
   Figure 69. Oncology Based Preclinical CRO Industrial Chain
   Figure 70. Methodology
   Figure 71. Research Process and Data Source